STATEMENTS OF CASH FLOWS - USD ($)	6 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (5,201,779)	$ (10,895,965)
Adjustments to reconcile net income (loss) to net cash used in operating activities:
Depreciation and amortization	316,083	308,259
Share-based payments for services	511,424	157,991
Equity based compensation	1,104,490	1,727,915
Common stock contributed to 401(k) plan	72,124	72,400
Shares issued for settlement of clinical research costs	1,290,000	1,247,400
Gain on derivative instruments	(4,589,135)	(196,585)
Amortization of debt discount	0	1,023,084
Capitalized lease interest	64,432	83,564
(Increase)/decrease in assets:
Receivables	(4,579)	81,698
Prepaid expenses	(74,741)	42,748
Inventory used for R&D and manufacturing	(115,774)	42,211
Deposits	0	150,000
Increase/(decrease) in liabilities:
Accounts payable	(1,489,234)	(541,767)
Accrued expenses	82,580	(33,966)
Due to employees	245,074	360,972
Other liabilities	(1,057)	2,638
Net cash used in operating activities	(7,790,092)	(6,367,403)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchases of equipment	(160,920)	0
Expenditures for patent costs	(67,661)	(1,113)
Net cash used in investing activities	(228,581)	(1,113)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of common stock and warrants	0	7,127,141
Payments of stock issuance costs	(80,224)	(62,004)
Proceeds from exercise of warrants	3,305,387	0
Payments on obligations under capital lease	(2,521)	(3,870)
Net cash provided by financing activities	3,222,642	7,061,267
NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS	(4,796,031)	692,751
CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD	10,310,044	2,369,438
CASH AND CASH EQUIVALENTS, END OF PERIOD	5,514,013	3,062,189
SUPPLEMENTAL SCHEDULE OF NON-CASH INVESTING AND FINANCING ACTIVITIES:
Capitalizable patent costs included in accounts payable	0	8,137
Capital lease obligation included in accounts payable	428	402
Stock issuance costs included in accounts payable	10,000	68,374
Prepaid consulting services paid with issuance of common stock	(83,415)	95,911
Notes payable converted into common shares	0	184,300
Cash paid for interest expense	$ 902,091	$ 872,087